SCAN Centre develops advanced diagnostic and monitoring technologies for neurodegenerative diseases. Key innovations include a blood-based Parkinson’s disease detection assay using amyloid amplification and a patented non-aggregating mutant, along with NeuroScan360, an AI-driven multimodal platform for early neurological disorder detection and longitudinal monitoring.